A prospective study of admissions for febrile neutropenia in secondary paediatric units in South East England

Pediatric Blood and Cancer

Volumn 49, Issue 5, 2007, Pages 678-681

  Duncan, C ^a   Chisholm, J C ^b   Freeman, S ^c   Riley, U ^a   Sharland, M ^d   Pritchard Jones, K ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c Bexley Care Trust   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Antibiotic resistance; Febrile neutropenia; Shared care

Indexed keywords

ANTIBIOTIC AGENT; GENTAMICIN; PIPTAZOBACTAM; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; BLOOD CULTURE; CHILDHOOD DISEASE; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG SAFETY; FEBRILE NEUTROPENIA; FUNGUS ISOLATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM; ADOLESCENT; CHILD; DRUG RESISTANCE; FEMALE; FEVER; FUNGUS; HOSPITAL; HOSPITALIZATION; INFANT; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; NEUTROPENIA; PRESCHOOL CHILD;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; ENGLAND; FEMALE; FEVER; FUNGI; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HOSPITALIZATION; HOSPITALS, PEDIATRIC; HUMANS; INFANT; MALE; NEUTROPENIA; PRACTICE GUIDELINES; PROSPECTIVE STUDIES;

EID: 35148870506     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21041     Document Type: Article

References (18)

1. Schimpff S, Satterlee W, Young VM, et al. Empiric therapy with cabenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971;284:1061-1065.
2. Malik IA. Out-patient management of febrile neutropenia in indigent paediatric patients. Ann Acad Med Singapore 1997;26: 742-746.
3. Petrilli AS, Dantas LS, Campos MC, et al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: Randomized prospective trial. Med Pediatr Oncol 1999;34: 87-91.
4. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low-risk pediatric patients with cancer. Cancer 1999;86:126-134.
5. Paganini HR, Sarkis CM, De Martino MG, et al. Oral administration of cefixime to lower risk febrile neutropenic children with cancer. Cancer 2000;88:2848-2852.
6. Paganini HR, Rodriguez-Brieshcke T, Zubizarreta P, et al. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia. Cancer 2001;91:1563-1567.
7. Paganini HR, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease. Cancer 2002;97:1775-1780.
8. Santolaya ME, Alvarez AM, Aviles C, et al. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever and neutropenia at low risk for invasive bacterial infection. J Clin Oncol 2004;22: 3784-3784.
9. Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four EORTC studies. Br J Haem 1997;99: 580-588.
10. Klaassen RJ, Goodman TR, Pham B, et al. 'Low-risk' prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000;18:1012-1019.
11. Baorto EP, Aquino VM, Mullen CA, et al. Clinical parameters associated with low bacteraemia risk in 1100 paediatric oncology patients with fever and neutropenia. Cancer 2001;92:909-913.
12. Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005;23:7958-7966.
13. Jones GR, Konsler GK, Dunaway RP, et al. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 1994;124:703-708.
14. Park JR, Coughlin J, Hawkins D, et al. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med Pediatr Oncol 2003;40:93-98.
15. Wehl G, Allerberger F, Heitger A, et al. Trends in infection morbidity in a paediatric oncology ward, 1986-1995. Med Pediatr Oncol 1999;32:336-343.
16. Mullen C, Petropoulos D, Roberts WM, et al. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Haematol/Oncol 1999;21:212-218.
17. Raisch D, Holdsworth MT, Winter SS, et al. Economic comparison of home-care-based versus hospital-based treatment of chemotherapy-induced febrile neutropenia. Value Health 2003;6: 158-166.
18. Shemesh E, Yaniv I, Drucker M, et al. Home intravenous antibiotic treatment for febrile episodes in immune-compromised pediatric patients. Med Pediatr Oncol 1998;30:95-100.